Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s stock price reached a new 52-week low on Monday . The company traded as low as $57.97 and last traded at $58.87, with a volume of 4445 shares changing hands. The stock had previously closed at $61.95.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on ZLDPF shares. Cantor Fitzgerald upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, January 21st. William Blair raised shares of Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a report on Friday, March 7th.
View Our Latest Report on Zealand Pharma A/S
Zealand Pharma A/S Price Performance
The firm has a 50 day simple moving average of $85.24 and a two-hundred day simple moving average of $100.37. The stock has a market capitalization of $4.44 billion, a P/E ratio of -26.48 and a beta of 0.81. The company has a quick ratio of 35.49, a current ratio of 35.49 and a debt-to-equity ratio of 0.03.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.19. The company had revenue of $1.30 million during the quarter, compared to analysts' expectations of $28.11 million. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. On average, equities research analysts expect that Zealand Pharma A/S will post -2.19 earnings per share for the current year.
About Zealand Pharma A/S
(
Get Free Report)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Featured Stories
Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
